文献速递心脑血管急症重症综合管理与镇静镇痛

易扩张性血肿:定义高血肿扩大风险与不良预后人群

Expansion-Prone Hematoma: Defining a Population at High Risk of Hematoma Growth and Poor Outcome.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论易扩张性血肿(混合征、黑洞征或岛征任一存在)可独立预测脑出血患者血肿扩大(OR 28.33)和不良预后(OR 5.67)。

该研究纳入2011年7月至2017年1月发病6小时内完成基线CT及随访CT的脑出血患者282例,将易扩张性血肿定义为存在混合征、黑洞征或岛征中至少一项。88例早期血肿扩大患者中69例(78.4%)有易扩张性血肿。易扩张性血肿预测血肿扩大和不良预后的敏感性和准确性高于任一单一影像标志物。多因素logistic回归校正混杂因素后,易扩张性血肿独立预测血肿扩大(OR 28.33;95%CI 12.95-61.98)和不良预后(OR 5.67;95%CI 2.82-11.40)。作者认为易扩张性血肿可能是未来抗扩张治疗的潜在靶点。

要点

  • 易扩张性血肿定义为平扫CT存在混合征、黑洞征或岛征中至少一项。
  • 282例脑出血患者中,88例早期血肿扩大,其中69例(78.4%)有易扩张性血肿。
  • 易扩张性血肿预测血肿扩大的敏感性和准确性高于任一单一影像标志物。
  • 校正混杂因素后,易扩张性血肿独立预测血肿扩大(OR 28.33;95%CI 12.95-61.98)。
  • 校正混杂因素后,易扩张性血肿独立预测不良预后(OR 5.67;95%CI 2.82-11.40)。

适用人群与场景

  • 发病6小时内完成基线CT并有随访CT的脑出血患者。

诊断标准与关键阈值

  • 易扩张性血肿:平扫CT存在混合征、黑洞征或岛征中至少一项。

研究设计与关键结果

  • 研究类型为队列研究,纳入2011年7月至2017年1月脑出血患者282例。
  • 88例早期血肿扩大患者中69例(78.4%)有易扩张性血肿。
  • 易扩张性血肿预测血肿扩大和不良预后的敏感性和准确性高于任一单一影像标志物。
  • 多因素logistic回归校正混杂因素后,易扩张性血肿独立预测血肿扩大(OR 28.33;95%CI 12.95-61.98)。
  • 多因素logistic回归校正混杂因素后,易扩张性血肿独立预测不良预后(OR 5.67;95%CI 2.82-11.40)。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为易扩张性血肿可能是未来临床研究中抗扩张治疗的潜在靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Noncontrast computed tomography (CT) markers are increasingly used for predicting hematoma expansion. The aim of our study was to investigate the predictive value of expansion-prone hematoma in predicting hematoma expansion and outcome in patients with intracerebral hemorrhage (ICH).

METHODS: Between July 2011 and January 2017, ICH patients who underwent baseline CT scan within 6 h of symptoms onset and follow-up CT scan were recruited into the study. Expansion-prone hematoma was defined as the presence of one or more of the following imaging markers: blend sign, black hole sign, or island sign. The diagnostic performance of blend sign, black hole sign, island sign, and expansion-prone hematoma in predicting hematoma expansion was assessed. Predictors of hematoma growth and poor outcome were analyzed using multivariable logistical regression analysis.

RESULTS: A total of 282 patients were included in our final analysis. Of 88 patients with early hematoma growth, 69 (78.4%) had expansion-prone hematoma. Expansion-prone hematoma had a higher sensitivity and accuracy for predicting hematoma expansion and poor outcome when compared with any single imaging marker. After adjustment for potential confounders, expansion-prone hematoma independently predicted hematoma expansion (OR 28.33; 95% CI 12.95-61.98) and poor outcome (OR 5.67; 95% CI 2.82-11.40) in multivariable logistic model.

CONCLUSION: Expansion-prone hematoma seems to be a better predictor than any single noncontrast CT marker for predicting hematoma expansion and poor outcome. Considering the high risk of hematoma expansion in these patients, expansion-prone hematoma may be a potential therapeutic target for anti-expansion treatment in future clinical studies.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Li Q, Shen YQ, Xie XF, et al. Expansion-Prone Hematoma: Defining a Population at High Risk of Hematoma Growth and Poor Outcome. Neurocrit Care. 2019. PMID: 30430380. doi:10.1007/s12028-018-0644-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。